Whether PD-1 /PD-L1 coexpression predicts a more severe prognosis is still unknown [9, 22], so the influence of anti-PD-1 treatment in MTC prognosis needs to be verified by more clinical trials. The gene discussed is PDCD1; the disease is medullary thyroid gland carcinoma.